Edition:
India

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

31.05USD
9:36pm IST
Change (% chg)

$-0.35 (-1.11%)
Prev Close
$31.40
Open
$31.52
Day's High
$31.52
Day's Low
$30.86
Volume
46,332
Avg. Vol
376,295
52-wk High
$55.94
52-wk Low
$28.02

Chart for

About

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin... (more)

Overall

Beta: 0.76
Market Cap(Mil.): $2,772.65
Shares Outstanding(Mil.): 72.64
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Medicines Co names Fred Eshelman executive chairman

* The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors

15 Nov 2017

BRIEF-SymBio Pharmaceuticals says arbitration against The Medicines Company

* Says co initiated an arbitration against The Medicines Company (MDCO) on Oct. 11, under the rules of International Chamber of Commerce, seeking damages arising out of MDCO's repudiation of the license agreement entered into between the co and MDCO on October 5, 2015, for the exclusive rights to develop and commercialize the patient-controlled pain management drug "SyB P-1501" (or "IONSYS") in Japan

13 Nov 2017

BRIEF-The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran

* The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran

06 Nov 2017

BRIEF-The Medicines Company reports third-quarter 2017 business and financial results

* The Medicines Company reports third-quarter 2017 business and financial results

25 Oct 2017

Alnylam's RNAi drug succeeds in key study, shares soar

Alnylam Pharmaceuticals Inc's RNAi-based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease-causing proteins.

21 Sep 2017

UPDATE 4-Alnylam's RNAi drug succeeds in key study, shares soar

* $1 bln peak sales expected for patisiran in 2023 - Credit Suisse

21 Sep 2017

BRIEF-The Medicines Company announces FDA approval of Vabomere

* The Medicines Company announces FDA approval of Vabomere (meropenem and vaborbactam)

30 Aug 2017

FDA approves Medicines Co's urinary tract infection drug

The U.S. Food and Drug Administration said on Tuesday it has approved Medicines Co's antibacterial drug for patients with complicated urinary tract infections (cUTI).

30 Aug 2017

BRIEF-Medicines Co reports Q2 GAAP loss per share $5.52 from continuing operations

* The Medicines Company reports second quarter 2017 business and financial results

09 Aug 2017

BRIEF-The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam stopped early for superior benefit-risk compared to best available therapy for CRE

* The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE

25 Jul 2017

Earnings vs. Estimates